SEARCH

Current Edition

autoimmune diseases

With new results, J&J’s $1B gamble on a targeted inflammation drug faces long odds

Izencitinib is a JAK inhibitor, a type of drug that blocks an enzyme involved in inflammation. The drug class is well-established, having already produced multiple …

Continue Reading →